MRNA Moderna Inc
Company Analysis
Latest News
Moderna and Merck Start Phase 3 mRNA Lung Cancer Trial, Targeting Relapse
Moderna and Merck have initiated a Phase 3 clinical trial for their personalized mRNA cancer vaccine, intismeran. The study, titled INTerpath-014, targets...
Moderna Shares Slump, Cooling Hantavirus Vaccine Hype
Moderna shares declined on May 13 as speculative interest in a hantavirus vaccine faded. Health officials reassured investors that a major hantavirus outbreak...
🔴 MRNA is trading 5.15% down today amid broader market weakness and hot PPI data
MRNA is trading at $50.52 (-5.15%) as broader market indices decline following hotter-than-expected PPI data and rising geopolitical tensions. • The stock is...
🔴 MRNA is trading 4.5% down today amid broader market weakness
MRNA is trading at $50.86 (-4.52%) amid broader market weakness fueled by hotter-than-expected PPI data and rising oil prices. • The stock is tracking...
Moderna Recognized by TIME as One of the World's Most Impactful Companies
TIME named Moderna one of the world's most impactful companies for 2026. The ranking, conducted with Statista, evaluates net-positive contributions to health,...
🟢 MRNA is trading 6% up today on positive flu and hantavirus vaccine data
MRNA is trading at $57.44 (+5.68%) on continued momentum following positive clinical data for its flu and hantavirus vaccine candidates. • The stock has...
🟢 MRNA is trading 4.66% up today, extending a rally fueled by landmark flu and hantavirus vaccine data
MRNA is trading at $56.88 (+4.66%) as shares extend a rally triggered by positive clinical data for its flu and hantavirus vaccine candidates. • The stock has...
Moderna's Hantavirus Bet and Flu Breakthrough Ignite a Rally — But Can a Company Burning Cash This Fast Outrun Its Own Pipeline Promises?
Shares of Moderna surged into Monday pre-market at $58.20, extending a scorching run that began last week with a ~24% gain from May 5 to today. The catalyst: a...
🟢 MRNA is trading 6.9% up today on hantavirus vaccine development and positive flu vaccine progress
MRNA is trading at $58.20 in pre-market, up 6.9% following the announcement of early-stage hantavirus vaccine development and positive progress in its flu...
Moderna Surges 14%, Driven by Hantavirus News and Flu Vaccine Success
Moderna Inc. (MRNA) shares rose as much as 14% on Friday, May 8, 2026. The company announced early-stage development of a hantavirus vaccine following a...
Moderna Rallies on Five-Year Cancer Vaccine Data, Pivots Away from Vaccine Development
Moderna and Merck announced positive five-year follow-up data for their personalized mRNA cancer vaccine combined with Keytruda, showing it maintained a 49%...
Moderna Shares Plunge as CEO Halts Funding for New Phase 3 Vaccine Trials
Moderna shares plunged 8.75% to $47.33 after CEO Stéphane Bancel announced the company would not fund new Phase 3 vaccine trials in the foreseeable future,...
🔴 Moderna is trading 3.26% down in pre-market after recent rally pullback
MRNA is trading at $50.18, down 3.26% in pre-market, as the stock experiences profit-taking following a dramatic two-day surge. The initial rally saw the...
Moderna CEO Stephane Bancel Announces Halt to New Late-Stage Vaccine Trial Investment
Moderna announced a major strategic pivot, ceasing investment in new late-stage vaccine trials and instead redirecting capital toward its oncology and heart...
🟢 Moderna is trading 3% up today on continued momentum from cancer vaccine data
MRNA is trading at $51.30 (+2.99%) amid ongoing gains after strong five-year Phase 2b data showed its personalized mRNA cancer therapy combined with Keytruda...
🟢 Moderna is trading 3.3% up in after-hours trading on positive oncology data momentum
MRNA is trading at $51.46 (+3.3%) in after-hours, extending the significant intraday rally (which closed at +15.8%) driven by positive five-year follow-up data...
🟢 Moderna is trading 3.05% up today after five-year cancer vaccine data shows sustained efficacy
MRNA is trading up 3.05% at $44.31 following the announcement of positive five-year follow-up data for its intismeran autogene combined with Keytruda in...
Moderna & Merck Report Sustained Positive 5-Year Data for Personalized Cancer Vaccine
Moderna and Merck announced positive five-year follow-up data from the Phase 2b study of intismeran autogene (mRNA-4157). This investigational personalized...
🟢 Moderna is trading 6% up today after lifting 2025 revenue outlook
MRNA is trading at $41.83 (+6.28%) after raising its 2025 revenue forecast to ~$1.9B and outlining major operating expense cuts. * The company reiterated...
Moderna Gains as European Patent Office Revokes Key Arbutus Patent
Moderna’s stock rose after the Board of Appeal of the European Patent Office revoked a patent held by Arbutus Biopharma. Moderna (MRNA) shares added...